<DOC>
	<DOCNO>NCT01711346</DOCNO>
	<brief_summary>The objective study ass post-infusion viability S-303 Red Blood Cells ( RBC ) measure 24 hour post-infusion recovery lifespan autologous RBCs prepare S-303 Treatment System RBC storage 35 day comparison conventional untreated RBCs store 35 day .</brief_summary>
	<brief_title>A Study Assess Recovery Lifespan Radiolabeled Autologous S303 Treated Red Blood Cells</brief_title>
	<detailed_description />
	<criteria>Age least 18 year , either gender Normal health status ( determine Investigator review medical history blood donor physical exam ) Complete blood count ( CBC ) ; include red blood cell ( RBC ) indices mean cell volume ( MCV ) , mean cell hemoglobin ( MCH ) , mean cell hemoglobin concentration ( MCHC ) , RBC distribution width ( RDW ) serum chemistry value within normal limit ( include calcium , bicarbonate , chloride , inorganic phosphate , potassium , sodium , cholesterol , glucose , total protein , triglyceride , lactate dehydrogenase ( LDH ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , total bilirubin , blood urea nitrogen ( BUN ) , creatinine ) . Values outside normal reference range think clinically significant may allow protocol exception . Minimum hemoglobin level 13 g/dL female 14.5 g/dL male subject Negative blood donor screen test panel human immunodeficiency virus ( HIV ) , Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) , human T cell leukemic virus ( HTLV ) , Syphilis , west nile virus ( WNV ) ( available ) Female subject childbearing potential male subject must agree use medically acceptable method contraception throughout study period . A barrier method contraception must include , regardless method . Meet exceed American Association Blood Banks ( AABB ) guideline blood donation ( exception travel deferral ) . Signed date informed consent form â€¢ Clinically significant acute chronic disease ( determined Investigator ) History RBC autoantibodies/autoimmune hemolytic anemia , RBC alloantibody , autoimmune disease History congenital red cell disorder include glucose 6 phosphate dehydrogenase ( G6PD ) deficiency Serum ferritin &lt; 12 ng/mL Positive direct antiglobulin test ( DAT ) indirect antiglobulin test ( IAT ) study entry Immunosuppressive therapy ( e.g. , oral Intravenous ( IV ) prednisone ) within past 28 day Treatment medication know affect RBC viability Pregnant nursing female Male subject female subject childbearing potential use effective contraception Participation another clinical study currently within past 28 day Prior exposure S 303 treat RBCs Preexisting antibody specific S 303 treat RBCs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>